Reality Check on Hemophilia B (Factor IX)
Market access for hemophilia B (factor IX) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 37% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In March 2021, uniQure said its experimental hemophilia B gene therapy was "highly unlikely" to have caused hepatocellular carcinoma (HCC) in one patient in a late-stage study testing the treatment, citing multiple analyses conducted by an independent laboratory and reviewed by leading external experts in the field. In December 2020, the FDA placed a clinical hold on the program due to a patient developing HCC
- Key Findings: Anticipated product approvals may develop improved product placement based on potential cost, adherence and efficacy advantages. The hemophilia market will be managed more tightly as we start seeing an increase in long-acting products
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.